Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

BACKGROUND: Ezatiostat, a glutathione S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic progenitors and induces apoptosis in cancer cells. RESULTS: Ezatiostat was administered to 19 patients with non-deletion(5q) myelodysplastic syndrome (MDS) at one of two doses (2000 mg or 250...

Descripción completa

Detalles Bibliográficos
Autores principales: Raza, Azra, Galili, Naomi, Mulford, Deborah, Smith, Scott E, Brown, Gail L, Steensma, David P, Lyons, Roger M, Boccia, Ralph, Sekeres, Mikkael A, Garcia-Manero, Guillermo, Mesa, Ruben A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3416694/
https://www.ncbi.nlm.nih.gov/pubmed/22546242
http://dx.doi.org/10.1186/1756-8722-5-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3416694/
https://www.ncbi.nlm.nih.gov/pubmed/22546242
http://dx.doi.org/10.1186/1756-8722-5-18

Ejemplares similares